Tengteng Yu

930 total citations
44 papers, 555 citations indexed

About

Tengteng Yu is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Tengteng Yu has authored 44 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 23 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Tengteng Yu's work include Multiple Myeloma Research and Treatments (31 papers), CAR-T cell therapy research (11 papers) and Protein Degradation and Inhibitors (11 papers). Tengteng Yu is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), CAR-T cell therapy research (11 papers) and Protein Degradation and Inhibitors (11 papers). Tengteng Yu collaborates with scholars based in China, United States and Taiwan. Tengteng Yu's co-authors include Kenneth C. Anderson, Yu‐Tzu Tai, Lijie Xing, Shih‐Feng Cho, Liang Lin, Kenneth Wen, Nikhil C. Munshi, Phillip A. Hsieh, Yuyin Li and Krista Kinneer and has published in prestigious journals such as Blood, Clinical Cancer Research and Leukemia.

In The Last Decade

Tengteng Yu

37 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tengteng Yu China 13 340 330 280 142 123 44 555
Lijie Xing China 14 364 1.1× 393 1.2× 336 1.2× 176 1.2× 136 1.1× 49 669
Chelsea J. Gudgeon United States 11 206 0.6× 308 0.9× 220 0.8× 177 1.2× 129 1.0× 16 532
Kimberly H. Harrington United States 11 307 0.9× 492 1.5× 343 1.2× 206 1.5× 254 2.1× 17 807
Phillip A. Hsieh United States 8 211 0.6× 239 0.7× 154 0.6× 103 0.7× 81 0.7× 16 339
Jenny Craigen United Kingdom 8 317 0.9× 375 1.1× 202 0.7× 197 1.4× 232 1.9× 11 660
Homer Adams United States 10 401 1.2× 401 1.2× 249 0.9× 237 1.7× 195 1.6× 25 713
Brandi Hilder United States 16 674 2.0× 593 1.8× 517 1.8× 154 1.1× 295 2.4× 43 978
Kristine A. Frerichs Netherlands 13 287 0.8× 286 0.9× 152 0.5× 136 1.0× 166 1.3× 19 452
R. Rossi United States 5 351 1.0× 318 1.0× 285 1.0× 220 1.5× 28 0.2× 6 681
Dionysos Slaga United States 8 86 0.3× 338 1.0× 208 0.7× 187 1.3× 321 2.6× 10 529

Countries citing papers authored by Tengteng Yu

Since Specialization
Citations

This map shows the geographic impact of Tengteng Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tengteng Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tengteng Yu more than expected).

Fields of papers citing papers by Tengteng Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tengteng Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tengteng Yu. The network helps show where Tengteng Yu may publish in the future.

Co-authorship network of co-authors of Tengteng Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Tengteng Yu. A scholar is included among the top collaborators of Tengteng Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tengteng Yu. Tengteng Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yan, Yuting, Tingyu Wang, Tengteng Yu, et al.. (2025). Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study. Clinical Cancer Research. 31(10). 1856–1864. 1 indexed citations
2.
Liu, Lanting, Hao Sun, Rui Lv, et al.. (2025). Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing. Haematologica. 110(11). 2726–2739. 1 indexed citations
3.
Xiong, Yu, Tengteng Yu, Shuaishuai Zhang, et al.. (2024). Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. Journal for ImmunoTherapy of Cancer. 12(11). e010080–e010080. 2 indexed citations
4.
5.
Xiong, Wenjie, Yuting Yan, Tingyu Wang, et al.. (2024). Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia. Blood. 144(Supplement 1). 1648–1648. 2 indexed citations
6.
Cui, Jian, Rui Lv, Tengteng Yu, et al.. (2023). Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma. Haematologica. 109(2). 591–603. 4 indexed citations
7.
Shi, Lihui, Lingna Li, Jian Cui, et al.. (2023). Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM). Annals of Hematology. 103(4). 1305–1315. 1 indexed citations
8.
Yu, Zhen, Xiaojing Wei, Lanting Liu, et al.. (2022). Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 78. 103950–103950. 27 indexed citations
9.
Xing, Lijie, Su Wang, Jiye Liu, et al.. (2021). BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clinical Cancer Research. 27(19). 5376–5388. 22 indexed citations
10.
Yu, Tengteng, Xiaoke Ma, Weiwei Sui, et al.. (2020). Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Molecular Cancer Research. 18(7). 1063–1073. 21 indexed citations
11.
Lin, Liang, Shih‐Feng Cho, Lijie Xing, et al.. (2020). Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 35(3). 752–763. 64 indexed citations
12.
Yu, Tengteng, Yan Xu, Gang An, et al.. (2020). Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clinical Lymphoma Myeloma & Leukemia. 20(10). e652–e659. 10 indexed citations
13.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2020). BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers. 12(6). 1473–1473. 45 indexed citations
14.
Xing, Lijie, Liang Lin, Tengteng Yu, et al.. (2020). A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 34(8). 2150–2162. 50 indexed citations
15.
Yu, Tengteng, Zhen Yu, Lei Zhao, et al.. (2019). PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e21–e22.
16.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2018). Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment. Blood. 132(Supplement 1). 592–592. 23 indexed citations
17.
Tai, Yu‐Tzu, Liang Lin, Lijie Xing, et al.. (2018). APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 33(2). 426–438. 66 indexed citations
18.
Qiu, Shaowei, Shuang Liu, Tengteng Yu, et al.. (2017). Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells. BMC Cancer. 17(1). 795–795. 2 indexed citations
19.
Cho, Shih‐Feng, Liang Lin, Lijie Xing, et al.. (2017). Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies. 6(4). 18–18. 11 indexed citations
20.
Lu, Wenting, Tengteng Yu, Shuang Liu, et al.. (2017). FHL2 interacts with iASPP and impacts the biological functions of leukemia cells. Oncotarget. 8(25). 40885–40895. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lijie Xing Breakdown of academic impact, for papers by Chelsea J. Gudgeon Breakdown of academic impact, for papers by Kimberly H. Harrington Breakdown of academic impact, for papers by Phillip A. Hsieh Breakdown of academic impact, for papers by Jenny Craigen Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Brandi Hilder Breakdown of academic impact, for papers by Kristine A. Frerichs Breakdown of academic impact, for papers by R. Rossi Breakdown of academic impact, for papers by Dionysos Slaga
Rankless by CCL
2026